Biosign and ADL Data Systems partner to address the $136 Billion Cost of
Adverse Drug Reactions in the United States

TORONTO, July 28 /CNW/ - Biosign Technologies Inc. (CNSX: BIO) ("Biosign", the "Company") and ADL Data Inc. ("ADL") announced that they will integrate Biosign's UFIT-based system for monitoring Cardio-Hemodynamic Adverse Response to Medication ("CHARM") with ADL's robust suite of Electronic Medical Record ("EMR") applications for delivery to skilled nursing homes and visiting nurse organizations.

Many patients experience complications from prescribed drugs. Often severe, these complications add significantly to the challenge of managing chronic conditions, such as heart disease and diabetes. Adverse Drug Reactions ("ADRs") are the 4th leading cause of death in the US. There are over 2 million serious ADRs per year, with about 100,000 deaths and an annual direct cost of $136 billion. In addition, hospital stays, costs, and mortality rates are double for patients with ADRs.

"The rate of ADRs in the nursing home segment is 350,000 per year, a number of epidemic proportions, far greater, proportionately, than in any other segment in healthcare. ADL has been providing solutions to nursing homes across the country for over 25 years. We are excited by the opportunity to provide a solution to this enormous problem and look forward to working with Biosign to address this problem from both quality of life and cost viewpoints", stated Robert Abrams, President of ADL.

Despite the well-known risks associated with using prescription drugs, medication errors, and adverse drug reactions, ADRs are still poorly understood and recorded. Given these risks, Biosign's CHARM system aims to provide an objective and standardized method to monitor and report these reactions and an individual's response to treatment.

"We have been working on CHARM since 2006. In collaboration with the Institute of Electrical and Electronics Engineers (IEEE), we organized yearly workshops in 2007, 2008, and 2009 aimed at providing technological solutions to identifying and mitigating ADRs risks. With CHARM, we address the imperative needs outlined by the World Health Organization, such as detecting and assessing safety signals rapidly and accurately, promoting the safe use of medicines, managing the risks of medicines judiciously, communicating timely and useful information to patients and practitioners, and actively engaging all stakeholders. We are pleased to see CHARM find its place as a trusted tool for improving the safety and efficacy of care in clinical settings", stated Radu Leca, President of Biosign.

CHARM includes a telematic health information system for monitoring responses to prescribed drugs, diet or exercise. The system will leverage ADL's EMR and the prescription regimen located in the ADL Clinical Information System to assess a patient's response to treatment, schedule UFIT readings, and evaluate the need to adjust treatment accordingly. When a potential ADR is recognized, CHARM shall issue an alert to the ADL clinician dashboard to allow clinicians the opportunity for prompt intervention. ADL will record the event in the patient prescription profile to avoid reoccurrences of a similar event and allow for multiple care teams to have access to the patients response to medications.

About Biosign Technologies Inc.

Biosign Technologies Inc. (CNSX: BIO) provides biomedical systems. Key applications include intelligent systems for noninvasive monitoring of common health risks associated with blood pressure, glucose, and medication. The core technology combines measurement, analysis, and rapid knowledge formation to support health monitoring across global markets. The UFIT(R) medical device technology powers quality data collection and analytics for clinical diagnostics, self-care, wellness, disease state evaluation & management, and remote patient monitoring. For more information on Biosign, please visit www.biosign.com.

About ADL Data Systems Inc.

ADL was founded in 1977 with a mission: "Design and develop the best clinical and financial software for nursing homes and long-term healthcare". Today, as a leading provider of software to over 250 Nursing Homes in the long term care industry, our software is helping long term care facilities and nursing home chains nationwide. Our applications cover a full range of administrative, financial, and clinical modules, and are used in nursing homes, CCRC's, rehabilitation facilities, and outpatient clinics. These modules empower users--nurses, therapists, administrators, Human Resources personnel--to meet the changing demands of their positions. We are committed to healthcare and to our users, healthcare professionals. ADL's reputation was earned with visionary design, quality products, custom programming and customer service. www.adldata.com

The CNSX has neither approved nor disapproved the contents of this press release.

%SEDAR: 00014068E

SOURCE Biosign Technologies Inc.

For further information: For further information: Radu Leca, Biosign Technologies Inc., Phone: (416) 218-9800 ext. 234, Email: ceo@biosign.com

Organization Profile

Biosign Technologies Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890